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CASE STUDY
Dexamethasone implant confined 
in Berger’s space
Pierre Dubrulle1, Franck Fajnkuchen1,2, Lise Qu1 and Audrey Giocanti‑Aurégan1*
Abstract 
We reported a new complication after dexamethasone implant injection. The patient was treated by dexamethasone 
implant injection for diabetic macular edema. After injection, we report an implant stucked in Berger’s space behind 
the crystalline lens capsule in the visual axis. This situation resolved after cataract surgery and the implant moved to a 
less inconvenient localization.
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Background
Dexamethasone implant is currently largely used in the 
treatment of diabetic macular edema, macular edema 
secondary to vein occlusions, uveitis or Irvine Gass syn-
drome. Efficacy and safety of this treatment are well doc-
umented. Complications of the implant injections such as 
migration in the anterior chamber throught iridotomy or 
in case of aphakia have already been described (Stepanov 
et al. 2015). Accidental injections into the crystalline lens 
(Coca-Robinot et  al. 2014; Fasce et  al. 2014) have also 
been reported. We describe here another complication 
after injection: the confinement of the implant in Berger’s 
space in the visual axis.
Case presentation
We report here the case of a 63 year-old diabetic woman 
presenting for diabetic macular edema and cataract. 
There was no history of previous blunt trauma to the 
eye. She was on oral hypoglycemic medications for 
her diabetes. On ophthalmological examination, best-
corrected visual acuity was 20/63 in both eyes. The slit 
lamp examination revealed a bilateral cataract. Intraocu-
lar pressure (IOP), measured by Goldmann applanation 
tonometry was 19 mm Hg in each eye. Discs were healthy 
and not cupped. There was a severe no proliferative 
diabetic retinopathy in both eyes. We diagnosed a cen-
tral diabetic macular edema on her left eye and decided 
to treat the edema before operating on cataract. A Dexa-
methasone implant injection was performed on her left 
eye. The injection technique and execution were unre-
markable. The needle was inserted 4 mm away from the 
limbus in the inferior and temporal quadrant, directly, 
without scleral path towards the center of the eye. The 
needle was advanced until the sleeve touches the con-
junctiva, and then the implant was injected.
Two days after injection, the patient was referred to the 
department complaining for floaters. On ophthalmologi-
cal examination, best-corrected visual acuity was 20/63 in 
the right eye and decreased at 20/125 in the left eye. The 
slit lamp examination after dilatation revealed the dexa-
methasone implant confined just behind the posterior 
capsule (Fig. 1). The implant only showed a little mobil-
ity and did not exit of this confined localization. What-
ever the position of the patient, prone position or seated, 
the implant was always visible in the pupillary area with-
out slit lamp, and did not change position. Examination 
of the fundus was unremarkable except for the severe 
non proliferative diabetic retinopathy. IOP measured by 
Goldmann was 21  mmHg in the left eye and a preven-
tive combination of timoptol and dorzolamide was pre-
scribed twice a day. The scheduled cataract surgery of the 
left eye was performed one month after Dexamethasone 
injection and was unremarkable. There was no accel-
eration of cataract development, and no evidence of lens 
traumatism visible during surgery.
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Seven days after surgery, in the left eye, best-corrected 
visual acuity was 20/32 and IOP at 26 mmHg under treat-
ment. The slit lamp examination after dilatation revealed 
the absence of dexamethasone implant in the visual axis 
(Fig. 2).
Discussion
Although complications of dexamethasone implant injec-
tions are rare, cases of retinal and vitreous hemorrhages 
after traumatic impact of a dexamethasone implant in 
vitrectomized eyes, or migration of the implant in the 
anterior chamber of the eye are described in the lit-
erature. To the best of our knowledge, this case of an 
implant confined in Berger’s space was not previously 
described. Berger’s space accumulation of pigment was 
already reported in cases of pigmentary glaucoma (Naga-
rajaiah and Shun-Shin 2011). It was observed that in case 
of break in Wieger’s ligament, corresponding to the con-
nexion between the edges of the anterior vitreous limit-
ing membrane and the periphery of the posterior surface 
of the lens, that pigment could flow in Berger’s space 
and accumulate there. Berger’s space corresponds to the 
space between the anterior hyaloid and posterior lens 
capsule. We suggested that for our patient, the implant 
lodged in this space after break of the Wieger’s ligament 
and stayed confined in this localization. Cataract surgery 
probably fragilized the Wieger’s ligament still intact and 
allowed the implant to move to a less inconvenient loca-
tion for our patient.
Conclusions
We describe here the confinement of dexamethasone 
implant in Berger’s space in the visual axis, a yet unde-
scribed complication after intravitreal injection.
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